62-469: ASPS may refer to: Advanced sleep phase syndrome , a sleep disorder in which patients feel very sleepy early in the evening American Society of Plastic Surgeons , the largest plastic surgery specialty organization in the world Alveolar soft part sarcoma , a rare type of soft tissue sarcoma tumor Association of Scottish Police Superintendents See also [ edit ] Asp (disambiguation) , for
124-401: A pedigree of the three FASPS kindreds which indicated a clear autosomal dominant transmission of the sleep phase advance. In 2001, the research group of Phyllis C. Zee phenotypically characterized an additional family affected with ASPS. This study involved an analysis of sleep/wake patterns, diurnal preferences (using a Horne-Östberg questionnaire), and the construction of a pedigree for
186-408: A CK1 binding site on the protein, allowing for phosphorylation which marks the protein for degradation, reducing protein levels. Once proteins become phosphorylated, PER2 levels decrease again, and Per2 mRNA transcription can resume. This negative feedback regulates the levels and expression of these circadian clock components. Without proper phosphorylation of hPER2 in the instance of a mutation in
248-544: A dietary supplement and, as such, has not approved it for any medical uses. It was approved for medical use in the European Union in 2007. Besides melatonin, certain synthetic melatonin receptor agonists like ramelteon , tasimelteon , and agomelatine are also used in medicine. In 2022, it was the 217th most commonly prescribed medication in the United States, with more than 1 million prescriptions. There
310-420: A free running circadian period of 22 hours, which is significantly shorter than the average human period of slightly over 24 hours. The shortened period associated with FASPS results in a shortened period of activity, causing earlier sleep onset and offset. This means that individuals with FASPS must delay their sleep onset and offset each day in order to entrain to the 24-hour day. On holidays and weekends, when
372-730: A hereditary circadian rhythm variant associated with a short endogenous (i.e. internally-derived) period. The subjects demonstrated a phase advance of sleep-wake rhythms that was distinct not only from control subjects, but also to sleep-wake schedules widely considered to be conventional. The subjects were also evaluated using the Horne-Östberg questionnaire , a structured self-assessment questionnaire used to determine morningness-eveningness in human circadian rhythms. The Horne-Östberg scores of first-degree relatives of affected individuals were higher than those of 'marry-in' spouses and unrelated control subjects. While much of morning and evening preference
434-533: A more socially acceptable time, causing them to losing sleep due to earlier-than-usual wakeup time. Another factor that distinguishes FASPS from other advanced sleep phase disorders is its strong familial tendency and life-long expression. Studies of affected lineages have found that approximately 50% of directly related family members experience the symptoms of FASPS, which is an autosomal dominant trait . Diagnosis of FASPS can be confirmed through genetic sequencing analysis by locating genetic mutations known to cause
496-457: A potentiating interaction, increasing the anticoagulant effect of warfarin and the risk of bleeding. Melatonin acts as an agonist of the melatonin MT 1 and MT 2 receptors , the biological targets of endogenous melatonin. Endogenous melatonin is normally secreted from the pineal gland of the brain. Melatonin is thought to activate melatonin receptors in the suprachiasmatic nucleus of
558-624: A study at the University of Utah in which he coined the term familial advanced sleep phase disorder after identifying individuals with a genetic basis for an advanced sleep phase. The first patient evaluated during the study reported "disabling early evening sleepiness" and "early morning awakening"; similar symptoms were also reported in her family members. Consenting relatives of the initial patient were evaluated, as well as those from two additional families. The clinical histories, sleep logs and actigraphy patterns of subject families were used to define
620-471: A substantial period of time to be correctly diagnosed. Individuals expressing the above symptoms may be diagnosed with ASPD using a variety of methods and tests. Sleep specialists measure the patient's sleep onset and offset, dim light melatonin onset, and evaluate Horne-Ostberg morningness-eveningness questionnaire results. Sleep specialists may also conduct a polysomnography test to rule out other sleep disorders like narcolepsy . Age and family history of
682-615: A treatment for cancer, but the National Cancer Institute found insufficient evidence for it. However, further research found it to slightly improve survival of patients and to alleviate chemotherapy-related side effects. Both animal and human studies have shown melatonin to protect against radiation-induced cellular damage. Melatonin and its metabolites protect organisms from oxidative stress by scavenging reactive oxygen species which are generated during exposure. Nearly 70% of biological damage caused by ionizing radiation
SECTION 10
#1732851866768744-406: Is a naturally occurring hormone produced in the brain that is also used as a dietary supplement and medication . As a hormone, melatonin is released by the pineal gland and is involved in sleep–wake cycles . As a supplement, it is often used for the attempted short-term treatment of disrupted sleep patterns, such as from jet lag or shift work , and is typically taken orally . There
806-512: Is a substituted tryptamine and a derivative of serotonin (5-hydroxytryptamine). It is structurally related to N-acetylserotonin (normelatonin; N -acetyl-5-hydroxytryptamine), which is the chemical intermediate between serotonin and melatonin in the body. Synthetic melatonin receptor agonists used in medicine like ramelteon , tasimelteon , agomelatine , and piromelatine (still in clinical trials) are analogues of melatonin. The first patent for its use in circadian rhythm disorders
868-452: Is a documented problem. 71% of products did not contain within 10% of the labelled amount of melatonin, with variations ranging from -83% to +478%, lot-to-lot variability was as high as 465%, and the discrepancies were not correlated to any manufacturer or product type. To make matters worse, 8 out of 31 products were contaminated with the neurotransmitter serotonin. Formerly, melatonin was derived from animal pineal tissue, such as bovine. It
930-495: Is about 1% in middle-age adults, and is believed to affect men and women equally. The disorder has a strong familial tendency , with 40-50% of affected individuals having relatives with ASPD. A genetic basis has been demonstrated in one form of ASPD, familial advanced sleep phase syndrome (FASPS), which implicates missense mutations in genes hPER2 and CKIdelta in producing the advanced sleep phase phenotype. The identification of two different genetic mutations suggests that there
992-435: Is also possible to buy raw melatonin powder by the weight. Immediate-release formulations of melatonin cause blood levels of melatonin to reach their peak in about an hour. The hormone may be administered orally, as capsules, gummies, tablets, oral films, or liquids. It is also available for use sublingually , or as transdermal patches . Several inhalation-based melatonin products with a wide range of doses are being sold but
1054-411: Is cleared in a single passage through the liver, a small amount is excreted in urine, and a small amount is found in saliva. Melatonin is excreted in the urine 2 to 5% as the unchanged drug. Melatonin has an elimination half-life of about 20 to 60 minutes. The half-life of prolonged-release melatonin (Circadin) is 3.5 to 4 hours. Melatonin, also known as N -acetyl-5-methoxytryptamine,
1116-472: Is conflicting whether melatonin supplementation may ameliorate or exacerbate symptoms due to immunomodulation . Melatonin can lower follicle-stimulating hormone levels. Melatonin's effects on human reproduction remain unclear. Some supplemental melatonin users report an increase in vivid dreaming . Extremely high doses of melatonin increased REM sleep time and dream activity in people both with and without narcolepsy . Increased use of melatonin in
1178-635: Is different from Wikidata All article disambiguation pages All disambiguation pages Advanced sleep phase syndrome Advanced Sleep Phase Disorder ( ASPD ), also known as the advanced sleep-phase type (ASPT) of circadian rhythm sleep disorder , is a condition that is characterized by a recurrent pattern of early evening (e.g. 7-9 PM) sleepiness and very early morning awakening (e.g. 2-4 AM). This sleep phase advancement can interfere with daily social and work schedules, and results in shortened sleep duration and excessive daytime sleepiness. The timing of sleep and melatonin levels are regulated by
1240-468: Is emerging evidence that the timing of taking exogenous melatonin in relation to food is also an important factor. Specifically, taking exogenous melatonin shortly after a meal is correlated with impaired glucose tolerance. Therefore, Rubio-Sastre and colleagues recommend waiting at least 2 hours after the last meal before taking a melatonin supplement. Melatonin can cause nausea , next-day grogginess , and irritability. In autoimmune disorders , evidence
1302-793: Is evidence of its benefit for this use, but is not strong. A 2017 review found that sleep onset occurred six minutes faster with use on average, but found no change in total time asleep. Side effects from melatonin supplements are minimal at low doses for short durations (the studies reported about equally for both melatonin and placebo). Side effects of melatonin are rare but may occur in 1 to 10 patients in 1,000. They may include somnolence , headaches , nausea , diarrhea , abnormal dreams , irritability , restlessness , insomnia , anxiety , migraine , lethargy , hyperactivity , dizziness , hypertension , abdominal pain , heartburn , mouth ulcers , dry mouth , hyperbilirubinaemia , dermatitis , night sweats , pruritus , rash , dry skin , pain in
SECTION 20
#17328518667681364-399: Is generally safer, and a better alternative, than many prescription and over-the-counter sleep aids if a sleeping medication must be used for an extended period of time. Low doses of melatonin are usually sufficient to produce a hypnotic effect in most people. Higher doses do not appear to result in a stronger effect but instead appear to cause drowsiness for a longer period of time. There
1426-496: Is heritable, the allele causing FASPS was hypothesized to have a quantitatively larger effect on clock function than the more common genetic variations that influence these preferences. Additionally, the circadian phase of subjects was determined using plasma melatonin and body core temperature measurements; these rhythms were both phase-advanced by 3–4 hours in FASPS subjects compared with control subjects. The Ptáček group also constructed
1488-432: Is heterogeneity of this disorder. While advanced sleep and wake times are relatively common, especially among older adults, the extreme phase advance characteristic of familial advanced sleep phase syndrome (also known as familial advanced sleep phase disorder) is rare. Individuals with FASPS fall asleep and wake up 4–6 hours earlier than the average population, generally sleeping from 7:30pm to 4:30am. They also have
1550-443: Is little evidence that melatonin supplementation is effective in treating insomnia in healthy children. Melatonin appears to be relatively safe in overdose . It has been administered at daily doses of up to 300 mg without causing clinically significant adverse reactions in the literature. The most commonly reported adverse effect of melatonin overdose is somnolence . Upon melatonin overdose, drowsiness may be expected and
1612-577: Is no good evidence that melatonin helps treat insomnia and its attempted use for this purpose is recommended against by the American Academy of Sleep Medicine . A prolonged-release form of melatonin is approved for use as a medication in Europe for the treatment of insomnia in certain people. Melatonin may be useful in the treatment of delayed sleep phase syndrome . Melatonin is known to reduce jet lag , especially in eastward travel. However, if it
1674-462: Is not recommended in people with autoimmune diseases due to lack of data in these individuals. Prolonged-release pharmaceutical melatonin (Circadin) contains lactose and should not be used in people with the lactase deficiency or glucose–galactose malabsorption . Use of melatonin is also not recommend in women who are pregnant or breastfeeding or in people with liver disease . Melatonin appears to cause very few side effects as tested in
1736-537: Is not taken at the correct time, it can instead delay adaptation. Melatonin appears to have limited use against the sleep problems of people who work shift work . Tentative evidence suggests that it increases the length of time people are able to sleep. Melatonin is a safer alternative than clonazepam in the treatment of REM sleep behavior disorder – a condition associated with the synucleinopathies like Parkinson's disease and dementia with Lewy bodies . However, clonazepam may be more effective. In any case,
1798-633: Is now synthetic, which limits the risk of contamination or the means of transmitting infectious material. Melatonin is the most popular over-the-counter sleep remedy in the United States, resulting in sales in excess of US$ 400 million during 2017. In 2022, it was the 217th most commonly prescribed medication in the United States, with more than 1 million prescriptions. Beverages and snacks containing melatonin were being sold in grocery stores, convenience stores, and clubs in May 2011. The FDA considered whether these food products could continue to be sold with
1860-487: Is then eliminated . Usual doses of exogenous melatonin of 1 to 12 mg produce melatonin concentrations 10 to 100 times higher than endogenous peak levels. The plasma protein binding of melatonin is approximately 60%. It is mainly bound to albumin , α 1 -acid glycoprotein , and high-density lipoprotein . The membrane transport proteins that move melatonin across a membrane include, but are not limited to, glucose transporters , including GLUT1 , and
1922-428: The biological targets of endogenous melatonin. It is thought to activate these receptors in the suprachiasmatic nucleus of the hypothalamus in the brain to regulate the circadian clock and sleep–wake cycles. Immediate-release melatonin has a short elimination half-life of about 20 to 50 minutes. Prolonged-release melatonin used as a medication has a half-life of 3.5 to 4 hours. Melatonin
ASPS - Misplaced Pages Continue
1984-513: The hypothalamus to regulate the circadian clock and sleep–wake cycles. When used several hours before sleep according to the phase response curve for melatonin in humans, small amounts (0.3 mg ) of melatonin shift the circadian clock earlier, thus promoting earlier sleep onset and morning awakening. The bioavailability of melatonin is between 2.5 and 50%. Melatonin is rapidly absorbed and distributed , reaching peak plasma concentrations after 60 minutes of administration, and
2046-556: The proton-driven oligopeptide transporters PEPT1 and PEPT2 . Melatonin is metabolized in the liver by cytochrome P450 enzyme CYP1A2 to 6-hydroxymelatonin . Metabolites are conjugated with sulfuric acid or glucuronic acid for excretion in the urine . Some of the metabolites formed via the reaction of melatonin with a free radical include cyclic 3-hydroxymelatonin , N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), and N1-acetyl-5-methoxykynuramine (AMK). In humans, 90% of orally administered exogenous melatonin
2108-480: The 21st century has significantly increased reports of melatonin overdose, calls to poison control centers, and related emergency department visits for children. The number of children who unintentionally ingested melatonin supplements in the US has increased 530% from 2012 to 2021. Over 4,000 reported ingestions required a hospital stay, and 287 children required intensive care. The American Academy of Sleep Medicine says there
2170-445: The CK1 binding site, less Per2 mRNA is transcribed and the period is shortened to less than 24 hours. Individuals with a shortened period due to this phosphorylation disruption entrain to a 24h light-dark cycle, which may lead to a phase advance, causing earlier sleep and wake patterns. However, a 22h period does not necessitate a phase shift, but a shift can be predicted depending on the time
2232-468: The FDA has found false claims that it cures cancer. As melatonin may cause harm in combination with certain medications or in the case of certain disorders, a doctor or pharmacist should be consulted before making a decision to take melatonin. In many countries, melatonin is recognized as a neurohormone and it cannot be sold over-the-counter. According to Harriet Hall caution is advisable, since quality control
2294-481: The PER2 mutation is not exclusively responsible for causing FASPS, current research has continued to evaluate cases in order to identify new mutations that contribute to the disorder. Two years after reporting the finding of FASPS, Ptáček's and Fu's groups published results of genetic sequencing analysis on a family with FASPS. They genetically mapped the FASPS locus to chromosome 2q where very little human genome sequencing
2356-585: The Ptáček group, this pattern suggests that the phenotype segregates as a single gene with an autosomal dominant mode of inheritance. In 2001, the research groups of Ptáček and Ying-Hui Fu published a genetic analysis of subjects experiencing the advanced sleep phase, implicating a mutation in the CK1 -binding region of PER2 in producing the FASPS behavioral phenotype. FASPS is the first disorder to link known core clock genes directly with human circadian sleep disorders. As
2418-458: The affected family. Consistent with established ASPS criteria, the evaluation of subject sleep architecture indicated that the advanced sleep phase was due to an alteration of circadian timing rather than an exogenous (i.e. externally-derived) disruption of sleep homeostasis, a mechanism of sleep regulation . Furthermore, the identified family was one in which an ASPS-affected member was present in every generation; consistent with earlier work done by
2480-439: The average person's sleep phase is delayed relative to their workday sleep phase, individuals with FASPS experience further advance in their sleep phase. Aside from the unusual timing of sleep, FASPS patients experience normal quality and quantity of sleep. Like general ASPD, this syndrome does not inherently cause negative impacts, however, sleep deprivation may be imposed by social norms causing individuals to delay sleep until
2542-546: The body's central circadian clock , which is located in the suprachiasmatic nucleus in the hypothalamus . Individuals with ASPD report being unable to stay awake until conventional bedtime, falling asleep too quickly and/or early in the evening, and being unable to stay asleep until their desired waking time, experiencing early morning insomnia . When someone has advanced sleep phase disorder their melatonin levels and core body temperature cycle hours earlier than an average person. These symptoms must be present and stable for
ASPS - Misplaced Pages Continue
2604-481: The brand name Circadin is approved for use in the European Union in the short-term treatment of insomnia in people age 55 and older. Melatonin is also available as an over-the-counter dietary supplement in many countries. It is available in both immediate-release and less commonly prolonged-release forms. The compound is available in supplements at doses ranging from 0.3 mg to 10 mg or more. It
2666-514: The circadian phenotype of these mutant individuals in vitro and an absence of said mutations in all tested control subjects. Fruit flies and mice engineered to carry the human mutation also demonstrated abnormal circadian phenotypes, although the mutant flies had a long circadian period while the mutant mice had a shorter period. The genetic differences between flies and mammals that account for this difference circadian phenotypes are not known. Most recently, Ptáček and Fu reported additional studies of
2728-722: The compound should be cleared within 12 hours. No special treatment is needed for melatonin overdose. Melatonin is metabolized mainly by CYP1A enzymes . As such, inhibitors and inducers of CYP1A enzymes, such as CYP1A2 , can modify melatonin metabolism and exposure. As an example, the CYP1A2 and CYP2C19 inhibitor fluvoxamine increases melatonin peak levels by 12-fold and overall exposure by 17-fold and this combination should be avoided. CYP1A2 inducers like cigarette smoking , carbamazepine , and rifampicin may reduce melatonin exposure due to induction of CYP1A2. In those taking warfarin , some evidence suggests there may exist
2790-400: The day and some patients may not complain of excessive daytime sleepiness. Social obligations may cause an individual to stay up later than their circadian rhythm requires, however, they will still wake up very early. If this cycle continues, it can lead to chronic sleep deprivation and other sleep disorders . ASPD is more common among middle and older adults. The estimated prevalence of ASPD
2852-539: The disorder. Treatment with sleep and wake scheduling and bright light therapy can be used to try to delay sleep phase to a more conventional time frame, however treatment of FASPS has proven largely unsuccessful. Bright light exposure in the evening (between 7:00 and 9:00), during the delay zone as indicated by the phase response curve to light, has been shown to delay circadian rhythms, resulting in later sleep onset and offset in patients with FASPS or other advanced sleep phase disorders. In 1999, Louis Ptáček conducted
2914-431: The extremities, symptoms of menopause , chest pain , glycosuria (sugar in the urine), proteinuria (protein in the urine), abnormal liver function tests, weight gain , mood swings , aggression , and grogginess after awakening. Its use is not recommended during pregnancy or breastfeeding or for those with liver disease . Melatonin acts as an agonist of the melatonin MT 1 and MT 2 receptors ,
2976-462: The hPER2 protein that resulted in hypophosphorylation of hPER2 in vitro. The hypophosphorylation of hPER2 disrupts the transcription-translation (negative) feedback loop (TTFL) required for regulating the stable production of hPER2 protein. In a wildtype individual, Per2 mRNA is transcribed and translated to form a PER2 protein. Large concentrations of PER2 protein inhibits further transcription of Per2 mRNA. CK1 regulates PER2 levels by binding to
3038-539: The human Per2 S662G mutation and generation of mice carrying the human mutation. These mice had a circadian period almost 2 hours shorter than wild-type animals under constant darkness. Genetic dosage studies of CKIδ on the Per2 S662G mutation revealed that depending on the binding site on Per2 that CK1δ interacts with, CK1δ may lead to hypo- or hyperphosphorylation of the Per2 gene. Melatonin (medication) Melatonin
3100-477: The label "dietary supplements". On 13 January 2010, it issued a Warning Letter to Innovative Beverage, creators of several beverages marketed as drinks, stating that melatonin, while legal as a dietary supplement, was not approved as a food additive . Bebida Beverage Company received a warning letter in 2015 for selling a melatonin-containing beverage. Some research supports an antidepressant and anxiolytic effect of melatonin. It has also been used to aid in
3162-638: The patient is also taken into consideration. Once diagnosed, ASPD may be treated with bright light therapy in the evenings, or behaviorally with chronotherapy , in order to delay sleep onset and offset. The use of pharmacological approaches to treatment are less successful due to the risks of administering sleep-promoting agents early in the morning. Additional methods of treatment, like timed melatonin administration or hypnotics have been proposed, but determining their safety and efficacy will require further research. Unlike other sleep disorders, ASPD does not necessarily disrupt normal functioning at work during
SECTION 50
#17328518667683224-466: The phosphorylation process of PER2) also causing FASPS. An A-to-G missense mutation resulted in a threonine-to-alanine alteration in the protein. This mutation prevented the proper phosphorylation of PER2. The evidence for both a mutation in the binding domain of PER2 and a mutation in CKIδ as causes of FASPS is strengthened by the lack of the FASPS phenotype in wild type individuals and by the observed change in
3286-634: The quality of evidence for both treatments is very low and it is unclear whether either is definitely effective. A 2020 Cochrane review found no evidence that melatonin helped sleep problems in people with moderate to severe dementia due to Alzheimer's disease . A 2019 review found that while melatonin may improve sleep in minimal cognitive impairment , after the onset of Alzheimer's disease it has little to no effect. Melatonin may, however, help with sundowning (increased confusion and restlessness at night) in people with dementia. A prolonged-release 2 mg oral formulation of melatonin sold under
3348-403: The safety remains to be evaluated. The American Academy of Sleep Medicine (AASM) said that the melatonin content in unregulated (without a USP verified mark) supplements can diverge widely from the claimed amount; a study found that the melatonin content ranged from one half to four times the stated dose. Contraindications of melatonin include hypersensitivity reactions among others. It
3410-460: The short term, up to three months, at low doses. Two systematic reviews found no adverse effects of exogenous melatonin in several clinical trials, and comparative trials found the adverse effects headaches, dizziness, nausea, and drowsiness were reported about equally for both melatonin and placebo . Prolonged-release melatonin is safe with long-term use of up to 12 months. Although not recommended for long-term use beyond this, low-dose melatonin
3472-502: The singular of Asps ASP (disambiguation) , for the singular of ASPs Topics referred to by the same term [REDACTED] This disambiguation page lists articles associated with the title ASPS . If an internal link led you here, you may wish to change the link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=ASPS&oldid=1151613904 " Category : Disambiguation pages Hidden categories: Short description
3534-498: The subject is exposed to the stimulus, visualized on a Phase Response Curve (PRC) . This is consistent with studies of the role of CK1ɛ (a unique member of the CK1 family) in the TTFL in mammals and more studies have been conducted looking at specific regions of the Per2 transcript. In 2005, Fu's and Ptáček's labs reported discovery of a mutation in CKIδ (a functionally redundant form of CK1ɛ in
3596-474: The treatment of manic episodes in bipolar disorder , although evidence for its effectiveness is still inconsistent. Other studies have shown that melatonin may help reduce some types of headaches, epigastric pain and heartburn . There have also been studies trying to prove the effectiveness of melatonin in relation to epilepsy , dysmenorrhea , delirium , and tinnitus , but little to no beneficial role has been found. Melatonin has also been tested as
3658-472: The true potential of melatonin is becoming evident, and the importance of the timing of treatment is becoming clear." It was approved for medical use in the European Union in 2007. Melatonin is categorized by the US Food and Drug Administration (FDA) as a dietary supplement, and is sold over-the-counter in both the US and Canada. FDA regulations applying to medications are not applicable to melatonin, though
3720-533: Was discovered in 1958. It is sold over-the-counter in Canada and the United States; in the United Kingdom, it is a prescription-only medication. In Australia and the European Union, it is indicated for difficulty sleeping in people over the age of 54. In the European Union, it is indicated for the treatment of insomnia in children and adolescents. The U.S. Food and Drug Administration (FDA) treats melatonin as
3782-422: Was granted in 1987 to Roger V Short and Stuart Armstrong at Monash University , and the first patent for its use as a low-dose sleep aid was granted to Richard Wurtman at MIT in 1995. Around the same time, the hormone got a lot of press as a possible treatment for many illnesses. The New England Journal of Medicine editorialized in 2000: "With these recent careful and precise observations in blind persons,
SECTION 60
#17328518667683844-468: Was then available. Thus, they identified and sequenced all the genes in the critical interval. One of these was Period2 ( Per2 ) which is a mammalian gene sufficient for the maintenance of circadian rhythms. Sequencing of the hPer2 gene ('h' denoting a human strain, as opposed to Drosophila or mouse strains) revealed a serine-to-glycine point mutation in the Casein Kinase I (CK1) binding domain of
#767232